switching between glp-1 agonists chart Schematic illustration of monoagonists, dual and triple Beyond a singular focus on

Engineering new ligands that specifically target multiple G protein-coupled receptors with desired activity profiles requires time-consuming and expensive cycles of design-make-test-analyse work

Gastrointestinal side effects are a little more common in the oral version than in the injectables

Although these mechanisms have been exploited to facilitate weight loss, these medications have also been indicated for patients with cardiovascular or renal diseases, all of which have caused a recent drastic rise in prescribing GLP-1 RAs

At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide

BCBS dropped GLP-1 weight loss drug coverage across multiple states

GLP-1 medications can provide major health benefits, but recent studies have raised questions about a possible link with NAION, a rare optic nerve condition that can cause sudden vision loss